These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 9762343)

  • 41. Molecular mechanisms responsible for the drug-induced posttranscriptional modulation of ribonucleotide reductase levels in a hydroxyurea-resistant mouse L cell line.
    McClarty GA; Chan AK; Choy BK; Thelander L; Wright JA
    Biochemistry; 1988 Sep; 27(19):7524-31. PubMed ID: 3061459
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Iron binding capacity of didox (3,4-dihydroxybenzohydroxamic acid) and amidox (3,4-dihydroxybenzamidoxime) new inhibitors of the enzyme ribonucleotide reductase.
    Fritzer-Szekeres M; Novotny L; Vachalkova A; Findenig G; Elford HL; Szekeres T
    Life Sci; 1997; 61(22):2231-7. PubMed ID: 9393942
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Leukemia L1210 cell lines resistant to ribonucleotide reductase inhibitors.
    Cory JG; Carter GL
    Cancer Res; 1988 Feb; 48(4):839-43. PubMed ID: 3276399
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Isolation of two cellular lines resistant to ribonucleotide reductase inhibitors to investigate the inhibitory activity of 2,2'-bipyridyl-6-carbothioamide.
    Nocentini G; Federici F; Armellini R; Franchetti P; Barzi A
    Anticancer Drugs; 1990 Dec; 1(2):171-7. PubMed ID: 2131050
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Molecular and cellular effects of hydroxyurea].
    Przybyszewski WM; Malec J
    Postepy Biochem; 1982; 28(3):353-72. PubMed ID: 6764665
    [No Abstract]   [Full Text] [Related]  

  • 46. Structure-Based Design, Synthesis, and Evaluation of 2'-(2-Hydroxyethyl)-2'-deoxyadenosine and the 5'-Diphosphate Derivative as Ribonucleotide Reductase Inhibitors.
    Sun D; Xu H; Wijerathna SR; Dealwis C; Lee RE
    ChemMedChem; 2009 Oct; 4(10):1649-56. PubMed ID: 19681093
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Toxicity of naturally occurring purine deoxyribonucleosides.
    Henderson JF; Scott FW; Lowe JK
    Pharmacol Ther; 1980; 8(3):573-604. PubMed ID: 6247724
    [No Abstract]   [Full Text] [Related]  

  • 48. Nucleic acid related compounds. 74. Synthesis and biological activity of 2'(and 3')-deoxy-2'(and 3')-methylenenucleoside analogues that function as mechanism-based inhibitors of S-adenosyl-L-homocysteine hydrolase and/or ribonucleotide reductase.
    Robins MJ; Samano V; Zhang W; Balzarini J; De Clercq E; Borchardt RT; Lee Y; Yuan CS
    J Med Chem; 1992 Jun; 35(12):2283-93. PubMed ID: 1613752
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Ribonucleotide reductase: an intracellular target for the male antifertility agent, gossypol.
    McClarty GA; Chan AK; Creasey DC; Wright JA
    Biochem Biophys Res Commun; 1985 Nov; 133(1):300-5. PubMed ID: 3907637
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Molecular mechanisms of drug resistance involving ribonucleotide reductase: hydroxyurea resistance in a series of clonally related mouse cell lines selected in the presence of increasing drug concentrations.
    Choy BK; McClarty GA; Chan AK; Thelander L; Wright JA
    Cancer Res; 1988 Apr; 48(8):2029-35. PubMed ID: 2832057
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Iron binding capacity of didox (3,4 dihydroxybenzohydroxamic acid) and amidox (3,4 dihydroxybenzamidoxime) two inhibitors of the enzyme ribonucleotide reductase.
    Fritzer-Szekeres M; Novotny L; Vachalkova A; Göbl R; Elford HL; Szekeres T
    Adv Exp Med Biol; 1998; 431():599-604. PubMed ID: 9598136
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Deoxyadenosine toxicity and cell cycle arrest in hydroxyurea-resistant S49 T-lymphoma cells.
    Albert DA; Nodzenski E
    Exp Cell Res; 1988 Dec; 179(2):417-28. PubMed ID: 3056732
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Inhibition of ribonucleotide reductase by alpha-(N)-heterocyclic carboxaldehyde thiosemicarbazones.
    Moore EC; Sartorelli AC
    Pharmacol Ther; 1984; 24(3):439-47. PubMed ID: 6379688
    [No Abstract]   [Full Text] [Related]  

  • 54. Characterization of a mouse cell line selected for hydroxyurea resistance by a stepwise procedure: drug-dependent overproduction of ribonucleotide reductase activity.
    McClarty GA; Chan AK; Wright JA
    Somat Cell Mol Genet; 1986 Mar; 12(2):121-31. PubMed ID: 3515584
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Inhibition of ribonucleotide reductase activity by IC202C.
    Iijima M; Someno T; Ishizuka M; Takeuchi T
    J Antibiot (Tokyo); 2001 Aug; 54(8):682-3. PubMed ID: 11592505
    [No Abstract]   [Full Text] [Related]  

  • 56. Ribonucleotide reductase activity and growth of glutathione-depleted mouse leukemia L1210 cells in vitro.
    Weckbecker G; Cory JG
    Cancer Lett; 1988 Jun; 40(3):257-64. PubMed ID: 3289734
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Differential effect of collaterally sensitive antimetabolites on P388 murine leukemia sensitive and resistant to adriamycin in vitro.
    Satyamoorthy K; Deshpande SS; Chitnis MP
    Neoplasma; 1989; 36(6):673-83. PubMed ID: 2515459
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Substituted 2-acylpyridine-alpha-(N)-hetarylhydrazones as inhibitors of ribonucleotide reductase activity and L1210 cell growth.
    Cory JG; Downes DL; Cory AH; Schaper KJ; Seydel JK
    Anticancer Res; 1994; 14(3A):875-9. PubMed ID: 8074487
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Bromodeoxyuridine mutagenesis and deoxyribonucleotide pool imbalance in mammalian cells.
    Ashman CR; Kaufman ER; Davidson RL
    Basic Life Sci; 1985; 31():391-408. PubMed ID: 3888181
    [No Abstract]   [Full Text] [Related]  

  • 60. Ribonucleotide reductase inhibitors: new strategies for cancer chemotherapy.
    Nocentini G
    Crit Rev Oncol Hematol; 1996 Mar; 22(2):89-126. PubMed ID: 8679103
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.